Company intelligence / Profile preview
DelSiTech
Turku, Varsinais-Suomi, Finlanddelsitech.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
DelSiTech is developing controlled-release drug products using its proprietary silica-based technology. It focuses on improving patient compliance with long-acting formulations.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculesBiologicsViral vectorsVaccinesProteinsPeptidesRNADNACarbohydrates
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Bayer Pharma AGAnticancer BioscienceInnovare R&DIveric BioOptifye TherapeuticsUnitaidMedImmuneSolani Therapeutics Ltd
Beyond the preview
Go deeper on DelSiTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DelSiTech.